Roche resolves cancer test dispute with Stanford affiliated startup

The deal brings to a close a clash over DNA sequencing technology for cancer detection, with both sides agreeing to dismiss their claims.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Roche sues over blockbuster cancer drug as key patent protection expires

19 August 2025 In a New Jersey lawsuit, Henlius and Organon are accused of submitting an aBLA for a biosimilar that infringes two dozen patents.

Americas

Tempus sues competitor over AI cancer diagnostic tech

18 March 2025 Complaint centres on AI-powered tools for cancer diagnostics | Tempus says its rival has a history of deliberately copying competitors’ technologies.

Biotechnology

Roche loses appeal to block market entry of rival cancer drug

7 July 2020 A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.

More features

Why AI is changing the patent rules faster than anyone can keep up

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Roche resolves cancer test dispute with Stanford affiliated startup

More on this story

Editor's picks

Editor's picks

More features